IL216843A - Melanocortin receptor-specific peptides - Google Patents

Melanocortin receptor-specific peptides

Info

Publication number
IL216843A
IL216843A IL216843A IL21684311A IL216843A IL 216843 A IL216843 A IL 216843A IL 216843 A IL216843 A IL 216843A IL 21684311 A IL21684311 A IL 21684311A IL 216843 A IL216843 A IL 216843A
Authority
IL
Israel
Prior art keywords
melanocortin receptor
specific peptides
peptides
melanocortin
receptor
Prior art date
Application number
IL216843A
Other languages
English (en)
Hebrew (he)
Other versions
IL216843A0 (en
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of IL216843A0 publication Critical patent/IL216843A0/en
Publication of IL216843A publication Critical patent/IL216843A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL216843A 2009-06-08 2011-12-08 Melanocortin receptor-specific peptides IL216843A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18492909P 2009-06-08 2009-06-08
PCT/US2010/037589 WO2010144344A2 (en) 2009-06-08 2010-06-07 Melanocortin receptor-specific peptides

Publications (2)

Publication Number Publication Date
IL216843A0 IL216843A0 (en) 2012-02-29
IL216843A true IL216843A (en) 2016-11-30

Family

ID=43309425

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216843A IL216843A (en) 2009-06-08 2011-12-08 Melanocortin receptor-specific peptides

Country Status (14)

Country Link
US (4) US8846601B2 (enExample)
EP (1) EP2440227B1 (enExample)
JP (1) JP5805632B2 (enExample)
KR (1) KR101726893B1 (enExample)
CN (2) CN102458436B (enExample)
AU (1) AU2010259008C1 (enExample)
BR (1) BRPI1009644B1 (enExample)
CA (1) CA2761607C (enExample)
EA (1) EA020959B1 (enExample)
IL (1) IL216843A (enExample)
MX (1) MX2011013117A (enExample)
NZ (1) NZ596617A (enExample)
WO (1) WO2010144344A2 (enExample)
ZA (1) ZA201200112B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
ES2732077T3 (es) 2011-12-29 2019-11-20 Rhythm Pharmaceuticals Inc Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
CN118240012A (zh) * 2013-03-15 2024-06-25 节奏制药公司 肽组合物
US10174078B2 (en) * 2014-04-25 2019-01-08 Phi Pharma Sa Keratan sulfate specific transporter molecules
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
ES2985734T3 (es) 2015-09-30 2024-11-07 Rhythm Pharmaceuticals Inc Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4
JP2019535702A (ja) * 2016-11-09 2019-12-12 ナンヤン テクノロジカル ユニヴァーシティー ジンセンチド及びジンセンチド様ペプチドの調製及び使用
EP3768245A4 (en) * 2018-03-23 2023-10-18 Palatin Technologies, Inc. MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC ADMINISTRATION
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
CN115279390A (zh) * 2020-02-03 2022-11-01 帕拉丁科技公司 反向酰胺连接的促黑素受体特异性环状肽
EP4100040A4 (en) * 2020-02-03 2024-06-05 Palatin Technologies, Inc. DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES
CN114890958B (zh) * 2022-02-23 2023-10-20 四川警察学院 双光子染料化合物、其制备方法及其应用
CN115521356B (zh) * 2022-08-17 2024-04-02 桂林医学院 一种具有美白功效的多肽及其应用
CN119529031B (zh) * 2024-11-27 2025-12-05 润辉生物技术（威海）有限公司 一种环肽衍生物及其制备方法与应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
JP3219096B2 (ja) 1990-05-10 2001-10-15 ニコメド ファーマ エイエス ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
JP2001506996A (ja) 1996-12-17 2001-05-29 クアドラント ホールディングス ケンブリッジ リミテッド メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体
PT949905E (pt) 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
JP2003534240A (ja) 2000-01-18 2003-11-18 メルク エンド カムパニー インコーポレーテッド 強力な選択的メラノコルチン−４受容体アンタゴニストとなる環状ペプチド
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
WO2001085930A2 (en) 2000-05-09 2001-11-15 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
DK1315750T3 (da) 2000-08-30 2007-06-11 Hoffmann La Roche Cykliske peptider med melanocortin-4-receptoragonistaktivitet
CN1571796A (zh) 2000-09-27 2005-01-26 宝洁公司 黑皮素受体配体
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
CA2453027A1 (en) 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
AU2003290886A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
US7183255B2 (en) 2003-02-26 2007-02-27 Intradialytic Pharmaceuticals Method for stabilizing blood pressure in hemodialysis subjects
WO2004099246A2 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
CN1809372A (zh) * 2003-06-19 2006-07-26 伊莱利利公司 黑皮质素受体4(mc4)激动剂及其用途
US20060293223A1 (en) 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20070293423A1 (en) 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
WO2005048967A1 (en) 2003-11-24 2005-06-02 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
ES2566801T3 (es) 2004-08-04 2016-04-15 Clinuvel Pharmaceuticals Limited Métodos de inducción de melanogénesis en un sujeto
ME01234B (me) 2004-10-25 2013-06-20 Centocor Inc Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe
US20080306008A1 (en) 2004-11-04 2008-12-11 Nova Nordisk A/S Peptides for Use in the Treatment of Obesity
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20110098213A1 (en) 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
JP2008519006A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
EP1863841A1 (en) 2005-03-17 2007-12-12 Novo Nordisk A/S Compounds for use in the treatment of obesity
EP2548568B1 (en) 2005-07-08 2018-01-10 Ipsen Pharma Melanocortin receptor ligands
RU2401841C2 (ru) 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Лиганды рецепторов меланокортинов
RU2008100218A (ru) 2005-07-18 2009-08-27 Ново Нордикс А/С (Dk) Пептиды для лечения ожирения
EP1957096A4 (en) 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
SI2056855T1 (sl) 2006-08-31 2015-01-30 Clinuvel Pharmaceuticals Limited Alfa-msh derivati za zdravljenje fotodermazoze
CN101177450A (zh) * 2006-11-09 2008-05-14 武汉聚奇医药科技有限公司 引发男性阴茎勃起和提高女性性欲的短肽
EP2104684A1 (en) 2007-01-18 2009-09-30 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
CN101302246B (zh) * 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
EP2300036B1 (en) * 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides

Also Published As

Publication number Publication date
AU2010259008A1 (en) 2011-11-24
EA020959B1 (ru) 2015-03-31
AU2010259008B2 (en) 2014-12-04
AU2010259008C1 (en) 2016-04-21
NZ596617A (en) 2014-04-30
EA201190338A1 (ru) 2012-06-29
EP2440227A4 (en) 2013-03-20
MX2011013117A (es) 2012-05-23
ZA201200112B (en) 2013-06-26
US20120178701A1 (en) 2012-07-12
EP2440227A2 (en) 2012-04-18
CA2761607A1 (en) 2010-12-16
KR20120092089A (ko) 2012-08-20
EP2440227B1 (en) 2017-10-18
BRPI1009644A2 (pt) 2020-06-23
WO2010144344A2 (en) 2010-12-16
US9458201B2 (en) 2016-10-04
KR101726893B1 (ko) 2017-04-13
US10179804B2 (en) 2019-01-15
US20140357575A1 (en) 2014-12-04
JP2012529433A (ja) 2012-11-22
US8846601B2 (en) 2014-09-30
US10632171B2 (en) 2020-04-28
JP5805632B2 (ja) 2015-11-04
US20160318977A1 (en) 2016-11-03
US20190216887A1 (en) 2019-07-18
CN102458436B (zh) 2015-06-03
WO2010144344A3 (en) 2011-02-03
CN102458436A (zh) 2012-05-16
CN105037502A (zh) 2015-11-11
BRPI1009644B1 (pt) 2022-02-08
IL216843A0 (en) 2012-02-29
CA2761607C (en) 2018-09-04

Similar Documents

Publication Publication Date Title
ZA201200128B (en) Melanocortin receptor-specific peptides
ZA201200112B (en) Melanocortin receptor-specific peptides
IL219947A0 (en) Melanocortin-1 receptor-specific cyclic peptides
IL219946A0 (en) Melanocortin-1 receptor-specific linear peptides
ZA201105852B (en) Antibiotic peptides
GB0914110D0 (en) Peptide libraries
AU331433S (en) Canister
EP2440572A4 (en) SPECIFIC PEPTIDES FROM LACTAM BRIDGE MELANOCORTIN RECEPTORS
GB2476465B (en) Recycling Technology
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0920981D0 (en) Peptides
ZA201108446B (en) FViII-DERIVED PEPTIDES
GB0918914D0 (en) Composite
ZA201203722B (en) Peptide
GB0921691D0 (en) Sophorolpid transporter protien
GB0901461D0 (en) Recycling
GB0920987D0 (en) Peptides
HK1169123A (en) Melanocortin receptor-specific peptides
GB0817978D0 (en) Peptides
GB0908570D0 (en) Key-boards
GB0911790D0 (en) Peptides
IL214496A0 (en) Short b-defensin-derived peptides
GB0909494D0 (en) Neuroprotective peptide
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed